Sönmez, ESönmez, ASBayindir, YCoskun, DAritürk, S2024-08-042024-08-0420020264-410X1873-2518https://doi.org/10.1016/S0264-410X(02)00452-8https://hdl.handle.net/11616/93462In this prospective study, our aim was to test the effect of simultaneous administration of preS2 and S containing recombinant hepatitis B vaccine (S2SRHB) with tetanus toxoid (TT) to the individuals who did not respond after three doses of hepatitis B vaccine previously. There were three groups (healthy individuals, pregnant women, hemodialysis patients), each was divided into two subgroups as groups A and B. Group A received S2SRHB + TT and group B received only S2SRHB. We found that in groups receiving both vaccines, both seroconversion rate and antibody titer level were significantly higher (P < 0.05). In conclusion, simultaneous administration of S2SRHB + TT is more effective than administration of S2SRHB alone. (C) 2002 Elsevier Science Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccesshepatitis B vaccinetetanus toxoidnonresponderArticle213-42432461245069910.1016/S0264-410X(02)00452-82-s2.0-0037073575Q1WOS:000179723900012Q1